|
Prolactinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Women with prolactinomas entering menopause have a higher chance of prolactin normalization of treatment compared with women in their reproductive years.
|
31686376 |
2020 |
|
Prolactinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The patients were divided according to PRL level (normal vs. elevated) and the presence or absence of prolactinoma symptoms.
|
31314867 |
2020 |
|
Prolactinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The association between prolactin level variation and prolactinoma size reduction remains unclear.
|
31770105 |
2020 |
|
Prolactinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
A review of evidence regarding prolactinoma pituitary MRI follow-up; techniques and sequences, recent data on possible gadolinium retention, the role and a review of T2-weighted images in the identification of prolactinomas and frequently encountered clinical scenarios, as well as MRI correlation with prolactin secretion, tumor growth and prediction of response to medical therapy are presented.
|
31659622 |
2020 |
|
Prolactinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Lactotroph adenomas, also called prolactinomas and prolactin-secreting adenomas, constitute nearly 80% of functioning pituitary tumors and about 30-50% of all adenomas in the clinical practice.
|
31641970 |
2020 |
|
Prolactinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
A strong correlation was found between prolactinoma volume and serum prolactin level (r = 0.831, p < 0.001).
|
31200381 |
2019 |
|
Prolactinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We hypothesize that the alteration of PRL actions in lactotrope homeostasis due to the dysregulation of any of the mechanisms of actions described above may contribute to the pathogenesis of prolactinomas.
|
30376668 |
2019 |
|
Prolactinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Herein, we survey the role of prolactin and prolactinomas in pregnancy while also outlining the therapeutic approach to prolactinoma during pregnancy.
|
30341577 |
2019 |
|
Prolactinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
The objective of this systematic review was to systematically assess the effect of reducing prolactin with dopamine agonist on established cardiovascular risk factors in patients with prolactinomas.
|
31518995 |
2019 |
|
Prolactinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
New insights into progesterone actions on prolactin secretion and prolactinoma development.
|
31521709 |
2019 |
|
Prolactinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Prolactinomas with lack of size regression and failure to reach normalization of PRL levels by 12 months may be considered for other management strategies.
|
31181361 |
2019 |
|
Prolactinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
The discovery of dopamine inhibitory effects on prolactin secretion has led to an era of successful dopaminergic therapy for prolactinomas.
|
30852578 |
2019 |
|
Prolactinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Prolactin-Secreting Lung Adenocarcinoma Metastatic to the Pituitary Mimicking a Prolactinoma: A Case Report.
|
30137505 |
2019 |
|
Prolactinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Conclusions Cabergoline effectively lowers prolactin levels and may reduce tumour mass in paediatric and adolescent patients with prolactinomas.
|
31323004 |
2019 |
|
Prolactinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Prolactin-secreting adenomas (prolactinomas) are the most common secreting adenomas of the pituitary.
|
30404098 |
2019 |
|
Prolactinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Prolactinomas are usually benign and controllable tumors as they express abundant levels of dopamine type 2 receptor (D2), and can be treated with dopaminergic drugs, effectively reducing prolactin levels and tumor volume.
|
30677777 |
2019 |
|
Prolactinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Finally, inhibition or overexpression of miR-1299 in primary tumor cells confirmed that drug-resistant prolactinoma promoted prolactin secretion by promoting miR-1299 expression and reducing intracellular FOXO1.
|
31582213 |
2019 |
|
Prolactinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
We enrolled 149 patients (108 F/41 M) with PRLs (110 micro/39 macro) and 143 subjects (100 F/43 M) with NFPA (n = 96, 56 micro/40 macro) or ES (n = 47), with normal serum prolactin.
|
30406929 |
2019 |
|
Prolactinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Examples include: association of prolactinomas with paternal deprivation and with stressful life events; pseudocyesis; acute life event-driven episodes of galactorrhea; episodes of rapid weight gain following a life event; prolactin surges (without associated cortisol surges) following some psychological stresses.
|
31062250 |
2019 |
|
Prolactinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
A significant negative relationship between prolactin levels and MCS (r = -0.30, P < 0.01) and PCS (r = -0.41, P < 0.01) were found in prolactinomas.
|
30548674 |
2019 |
|
Prolactinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
PRL values >250 ng/mL are highly suggestive of prolactinomas and virtually exclude nonfunctioning pituitary adenomas (NFPAs) and other sellar masses as the etiology of hyperprolactinemia.
|
30889571 |
2019 |
|
Prolactinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
mPRs represent a novel target for PRL inhibition in experimental prolactinomas.
|
30856609 |
2019 |
|
Prolactinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Pituitary adenomas (PAs) are one of the most common intracranial tumors; approximately half of PAs are prolactin (PRL)-secreting PAs (prolactinomas).
|
31692290 |
2019 |
|
Prolactinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
At diagnosis, heterogeneous prolactinomas were more frequent in men (68% vs. 28.9%, p ≤ 0.011), larger (median area 304.5 mm<sup>2</sup> vs. 56.5 mm<sup>2</sup>, p ≤ 0.021), taller (mean height 18.6 mm vs. 9.9 mm, p < 0.001), more secreting (median PRL ULN_area 23 µg/L/cm<sup>2</sup> vs. 12.6 µg/L/cm<sup>2</sup>, p ≤ 0.032) and had poorer hormonal response to DA as compared with homogeneous prolactinomas.
|
30267354 |
2019 |
|
Prolactinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
22% of the respondents considered that prolactin levels <100 ng/mL exclude the presence of a prolactinoma.
|
30352394 |
2018 |